Physician profile
David Feerst
NPI 1508931767
$2,187.00
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $353.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $234.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.85 | 2019 | |
| Lilly USA, LLC | $171.78 | 2019-2020 | |
| Amgen INC. | $130.42 | 2019-2020 | |
| Allergan, INC. | $101.52 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $65.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $65.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.14 | 2019 | |
| Glaxosmithkline, LLC. | $51.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $37.72 | 2019 | |
| Amarin Pharma, INC. | $32.65 | 2019 | |
| Pfizer INC. | $32.25 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.45 | 2019 | |
| Ibsa Pharma INC. | $24.68 | 2019 | |
| Bausch Health US, LLC | $17.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 2019 | |
| Currax Pharmaceuticals LLC | $13.03 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feerst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.